| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Tetrabenazine (JAN/INN); Nitoman (TN); Xenazine (TN) | ||||||||||
| Product | XENAZINE (Lundbeck Pharmaceuticals LLC) | ||||||||||
| Generic | TETRABENAZINE (Ajanta Pharma USA), TETRABENAZINE (Apotex Corp.), TETRABENAZINE (AvKARE), TETRABENAZINE (Bionpharma), TETRABENAZINE (Camber Pharmaceuticals), TETRABENAZINE (Dr. Reddys Laboratories), TETRABENAZINE (Golden State Medical Supply), TETRABENAZINE (Hikma Pharmaceuticals USA), TETRABENAZINE (Lupin Pharmaceuticals), TETRABENAZINE (Oceanside Pharmaceuticals), TETRABENAZINE (Slate Run Pharmaceuticals), TETRABENAZINE (Sun Pharmaceutical Industries), TETRABENAZINE (TAGI Pharma) | ||||||||||
| Formula | C19H27NO3 | ||||||||||
| Exact mass | 317.1991 | ||||||||||
| Mol weight | 317.4226 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Metabolizing enzyme substrate DG01892 CYP1A2 substrate DG01644 CYP2D6 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate DG02972 CBR substrate | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Neuroleptic, Vesicular monoamine transporter inhibitor | ||||||||||
| Disease | Huntington's disease [DS:H00059] | ||||||||||
| Target | SLC18A2 (VMAT2) [HSA:6571] [KO:K08155] | ||||||||||
| Pathway |
| ||||||||||
| Metabolism | Enzyme: CYP2D6 [HSA:1565]; CYP3A4 [HSA:1576], CYP1A2 [HSA:1544], CBR [HSA:873 874] | ||||||||||
| Interaction | |||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N07 OTHER NERVOUS SYSTEM DRUGS N07X OTHER NERVOUS SYSTEM DRUGS N07XX Other nervous system drugs N07XX06 Tetrabenazine D08575 Tetrabenazine (JAN/INN) <JP/US> USP drug classification [BR:br08302] Central Nervous System Agents Central Nervous System, Other Tetrabenazine D08575 Tetrabenazine (JAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 1 Agents affecting nervous system and sensory organs 11 Agents affecting central nervous system 119 Miscellaneous 1190 Miscellaneous D08575 Tetrabenazine (JAN/INN) Drug groups [BR:br08330] Metabolizing enzyme substrate DG01892 CYP1A2 substrate D08575 Tetrabenazine DG01644 CYP2D6 substrate D08575 Tetrabenazine DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D08575 Tetrabenazine DG02972 CBR substrate D08575 Tetrabenazine Target-based classification of drugs [BR:br08310] Transporters Solute carrier family SLC18 SLC18A2 (VMAT2) D08575 Tetrabenazine (JAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D08575 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D08575 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D08575 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D08575 Pharmacogenomic biomarkers [br08341.html] Polymorphisms and mutations affecting drug response D08575 | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 23 1 C1x C 24.2200 -16.8700 2 C1y C 24.2200 -18.2700 3 N1y N 25.4100 -18.9700 4 C1x C 26.6700 -18.2700 5 C1y C 26.6700 -16.8700 6 C5x C 25.4100 -16.1700 7 C8y C 23.0300 -18.9700 8 C8y C 23.0300 -20.3700 9 C1x C 24.2200 -21.0700 10 C1x C 25.4100 -20.3700 11 C8y C 20.5800 -18.9700 12 C8y C 20.5800 -20.3700 13 C8x C 21.7700 -21.0700 14 C8x C 21.7700 -18.2700 15 O5x O 25.4100 -14.7700 16 C1b C 27.8600 -16.1700 17 C1c C 29.0500 -16.8700 18 C1a C 30.2400 -16.1700 19 C1a C 29.0500 -18.2700 20 O2a O 19.3900 -18.2700 21 O2a O 19.3900 -21.0700 22 C1a C 18.1300 -18.9700 23 C1a C 18.1300 -20.3700 BOND 25 1 5 6 1 2 6 1 1 3 11 12 2 4 12 13 1 5 13 8 2 6 7 14 2 7 14 11 1 8 1 2 1 9 6 15 2 10 2 3 1 11 5 16 1 12 3 4 1 13 16 17 1 14 7 8 1 15 17 18 1 16 8 9 1 17 17 19 1 18 9 10 1 19 11 20 1 20 10 3 1 21 12 21 1 22 2 7 1 23 20 22 1 24 4 5 1 25 21 23 1 |